If the addition of calcium channel blockers is ineffective or contraindicated, mineralocorticoid receptor antagonists might be considered as a third- or second-line treatment especially in those cases with coexisting hypokalemia (430, 431). Here, NR3C2 is linked to Hypokalemia.